Navigation Links
GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:8/26/2009

IV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press rele
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , Jan. 26 The following is a ... PharmAthene, regarding the Commission on the Prevention of Weapons of ... Card by the Commission on the Prevention of Weapons of ... America still remains vulnerable to bioterrorism.  Our Nation,s ability to ...
... , , TUALATIN, Ore. ... Bulletin Board: WYNX), a platform company dedicated to the ... announced that it has reached an agreement with British-based ... second generation Gas Quality Inferential Measurement Device (GasPT2). , ...
... Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... that it may now enroll patients at US clinical sites ... lead product, nimotuzumab. One of the two trials is in ... treatment and being treated palliatively and the other in patients ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 3YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 5
(Date:7/9/2014)... New Rochelle, NY, July 9, 2014Biofuels derived from the ... alternative to fossil fuels. To achieve this goal, optimization ... as in open pond systems, is needed. Sapphire Energy ... contamination of open pond algae cultivation systems, described in ... Ann Liebert, Inc., publishers. The article is available on ...
(Date:7/9/2014)... a University of Guelph scientist that involved fitting ... exposure to a neonicotinoid pesticide hampers bees, ability ... Nigel Raine, a professor in Guelph,s School of ... London was published July 9 in the British ... The study shows how long-term pesticide exposure affects ...
(Date:7/9/2014)... A new study shows that some shark species may be ... that may come with rising temperatures. , The Arctic today ... but it wasn,t always like that. Roughly 53 to 38 ... epoch, the Arctic was more similar to a huge temperate ... life, including ancestors of tapirs, hippo-like creatures, crocodiles and giant ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... researchers have identified the job of one of the ... puzzled scientists because it is present in nearly every ... and yet, in laboratory experiments, its function has remained ... enigmatic enzyme known as DinB DNA polymerase is specialized ...
... have identified a handful of microRNAs (miRNAs) that appear ... platelets ?blood cells critical to the body's ability to ... of these same miRNAs, when acting abnormally, may contribute ... that a specific set of miRNA genes are turned ...
... and slow developing gills appear to be keys to ... fish whose adults thrive in icy waters because of ... are important, researchers at the University of Illinois atUrbana-Champaign ... species of notothenioids that inhabit the Ross Sea at ...
Cached Biology News:Common enzyme is a key player in DNA repair 2Common enzyme is a key player in DNA repair 3MiRNA fingerprint identified in platelet formation 2Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: